PFE Earnings Date & History
Pfizer Inc (NEW YORK STOCK EXCHANGE, INC.) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 6:22 PM ET
Pfizer Inc
Pharmaceuticals
- Next earnings date
- Monday, November 2, 2026
- Reporting session
- Time TBD
- EPS estimate
- $0.78
- Revenue estimate
- $16.07B
PFE earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Tuesday, August 4, 2026 | Q2 2026 | $0.69 | $0.77 | +11.4% | $15.03B |
| Tuesday, May 5, 2026 | Q1 2026 | $0.72 | $0.75 | +3.5% | $14.45B |
| Tuesday, February 3, 2026 | Q4 2025 | $0.58 | $0.66 | +14.3% | $17.56B |
| Tuesday, November 4, 2025 | Q3 2025 | $0.64 | $0.87 | +36.0% | $16.65B |
| Tuesday, August 5, 2025 | Q2 2025 | $0.59 | $0.78 | +32.9% | $14.65B |
What the market is watching in PFE's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next PFE earnings date?
- Pfizer Inc is scheduled to report on Monday, November 2, 2026 (Time TBD). Dates can change until the company confirms them.
- Does PFE report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for PFE?
- Consensus EPS for the upcoming quarter is $0.78, on revenue of $16.07B.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
PFE earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.